Overman Michael J, Hoff Paulo M
Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Dis Colon Rectum. 2007 Aug;50(8):1259-70. doi: 10.1007/s10350-007-0228-3.
The management of colorectal cancer relies heavily on the combination of the pyrimidine analog antimetabolite 5-fluorouracil with the platinum-based drug oxaliplatin or the topoisomerase inhibitor irinotecan. Optimization of dosing and scheduling of these agents to improve response and survival continues to evolve. Meanwhile, the rational targeting of molecular signaling pathways that are involved in the etiology of malignancies is currently one of the most promising strategies in novel anticancer drug development. New classes of drugs that target the epidermal growth factor receptor are among the most clinically advanced molecular-targeted therapies and have shown efficacy in colorectal cancer. The current status of epidermal growth factor receptor-targeted therapeutic agents is reviewed, with emphasis on their role in the management of colorectal cancer.
结直肠癌的治疗严重依赖于嘧啶类似物抗代谢药5-氟尿嘧啶与铂类药物奥沙利铂或拓扑异构酶抑制剂伊立替康的联合使用。对这些药物的剂量和给药方案进行优化以提高疗效和生存率的研究仍在不断发展。与此同时，合理靶向参与恶性肿瘤病因学的分子信号通路目前是新型抗癌药物研发中最有前景的策略之一。靶向表皮生长因子受体的新型药物是临床上最先进的分子靶向治疗药物之一，已在结直肠癌中显示出疗效。本文综述了表皮生长因子受体靶向治疗药物的现状，重点阐述了它们在结直肠癌治疗中的作用。
